Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Truncated glioma-associated oncogene homolog 1 (tGLI1) mediates mesenchymal glioblastoma via transcriptional activation of CD44.

Rimkus TK, Carpenter RL, Sirkisoon SR, Zhu D, Pasche B, Chan MD, Lesser GJ, Tatter SB, Watabe K, Debinski W, Lo HW.

Cancer Res. 2018 Feb 20. pii: canres.2933.2017. doi: 10.1158/0008-5472.CAN-17-2933. [Epub ahead of print]

PMID:
29463580
2.

Atad3a suppresses Pink1-dependent mitophagy to maintain homeostasis of hematopoietic progenitor cells.

Jin G, Xu C, Zhang X, Long J, Rezaeian AH, Liu C, Furth ME, Kridel S, Pasche B, Bian XW, Lin HK.

Nat Immunol. 2018 Jan;19(1):29-40. doi: 10.1038/s41590-017-0002-1. Epub 2017 Nov 21.

PMID:
29242539
3.

Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?

Yang M, Forbes ME, Bitting RL, O'Neill SS, Chou PC, Topaloglu U, Miller LD, Hawkins GA, Grant SC, DeYoung BR, Petty WJ, Chen K, Pasche BC, Zhang W.

Ann Oncol. 2018 Feb 1;29(2):311-323. doi: 10.1093/annonc/mdx766.

PMID:
29216340
4.

Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth.

Carpenter RL, Sirkisoon S, Zhu D, Rimkus T, Harrison A, Anderson A, Paw I, Qasem S, Xing F, Liu Y, Chan M, Metheny-Barlow L, Pasche BC, Debinski W, Watabe K, Lo HW.

Oncotarget. 2017 May 22;8(43):73947-73963. doi: 10.18632/oncotarget.18166. eCollection 2017 Sep 26.

5.

Use of non-ionizing electromagnetic fields for the treatment of cancer.

Jimenez H, Blackman C, Lesser G, Debinski W, Chan M, Sharma S, Watabe K, Lo HW, Thomas A, Godwin D, Blackstock W, Mudry A, Posey J, O'Connor R, Brezovich I, Bonin K, Kim-Shapiro D, Barbault A, Pasche B.

Front Biosci (Landmark Ed). 2018 Jan 1;23:284-297.

PMID:
28930547
6.

Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center.

Kytola V, Topaloglu U, Miller LD, Bitting RL, Goodman MM, D Agostino RB Jr, Desnoyers RJ, Albright C, Yacoub G, Qasem SA, DeYoung B, Thorsson V, Shmulevich I, Yang M, Shcherban A, Pagni M, Liu L, Nykter M, Chen K, Hawkins GA, Grant SC, Petty WJ, Alistar AT, Levine EA, Staren ED, Langefeld CD, Miller V, Singal G, Petro RM, Robinson M, Blackstock W, Powell BL, Wagner LI, Foley KL, Abraham E, Pasche B, Zhang W.

Theranostics. 2017 Jul 12;7(11):2914-2923. doi: 10.7150/thno.20355. eCollection 2017.

7.

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.

Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R Jr, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B.

Lancet Oncol. 2017 Jun;18(6):770-778. doi: 10.1016/S1470-2045(17)30314-5. Epub 2017 May 8.

PMID:
28495639
8.

Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.

Yang M, Topaloglu U, Petty WJ, Pagni M, Foley KL, Grant SC, Robinson M, Bitting RL, Thomas A, Alistar AT, Desnoyers RJ, Goodman M, Albright C, Porosnicu M, Vatca M, Qasem SA, DeYoung B, Kytola V, Nykter M, Chen K, Levine EA, Staren ED, D'Agostino RB Jr, Petro RM, Blackstock W, Powell BL, Abraham E, Pasche B, Zhang W.

J Hematol Oncol. 2017 May 4;10(1):100. doi: 10.1186/s13045-017-0468-1.

9.

Lynch Syndrome Testing: A Missed Opportunity in the Era of Precision Medicine.

Pasche B, Pennison MJ, DeYoung B.

JAMA. 2016 Jul 5;316(1):38-9. doi: 10.1001/jama.2016.8291. No abstract available.

PMID:
27380341
10.

Activation of the c-Met Pathway Mobilizes an Inflammatory Network in the Brain Microenvironment to Promote Brain Metastasis of Breast Cancer.

Xing F, Liu Y, Sharma S, Wu K, Chan MD, Lo HW, Carpenter RL, Metheny-Barlow LJ, Zhou X, Qasem SA, Pasche B, Watabe K.

Cancer Res. 2016 Sep 1;76(17):4970-80. doi: 10.1158/0008-5472.CAN-15-3541. Epub 2016 Jun 30.

11.

Loss of TGFβ signaling promotes colon cancer progression and tumor-associated inflammation.

Principe DR, DeCant B, Staudacher J, Vitello D, Mangan RJ, Wayne EA, Mascariñas E, Diaz AM, Bauer J, McKinney RD, Khazaie K, Pasche B, Dawson DW, Munshi HG, Grippo PJ, Jung B.

Oncotarget. 2017 Jan 17;8(3):3826-3839. doi: 10.18632/oncotarget.9830.

12.

An HF exposure system for mice with improved efficiency.

Capstick M, Gong Y, Pasche B, Kuster N.

Bioelectromagnetics. 2016 May;37(4):223-33. doi: 10.1002/bem.21969. Epub 2016 Mar 31.

PMID:
27037618
13.

TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis.

Principe DR, DeCant B, Mascariñas E, Wayne EA, Diaz AM, Akagi N, Hwang R, Pasche B, Dawson DW, Fang D, Bentrem DJ, Munshi HG, Jung B, Grippo PJ.

Cancer Res. 2016 May 1;76(9):2525-39. doi: 10.1158/0008-5472.CAN-15-1293. Epub 2016 Mar 15.

14.

Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.

Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, Garber JE, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Pasche B, Reiser G, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wiesner GL, Dwyer MA, Kumar R; National comprehensive cancer network.

J Natl Compr Canc Netw. 2014 Sep;12(9):1326-38.

PMID:
25190698
15.

TGFBR1 and cancer susceptibility.

Pasche B, Pennison MJ, Jimenez H, Wang M.

Trans Am Clin Climatol Assoc. 2014;125:300-12. Review.

16.

Prevention and treatment of cancer with aspirin: where do we stand?

Pasche B, Wang M, Pennison M, Jimenez H.

Semin Oncol. 2014 Jun;41(3):397-401. doi: 10.1053/j.seminoncol.2014.04.012. Epub 2014 Apr 24. Review.

17.

Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design.

Pasche B, Grant SC.

JAMA. 2014 May 21;311(19):1975-6. doi: 10.1001/jama.2014.3742. No abstract available.

PMID:
24846033
18.

TGF-β: duality of function between tumor prevention and carcinogenesis.

Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, Pasche B, Lee C, Grippo PJ.

J Natl Cancer Inst. 2014 Feb;106(2):djt369. doi: 10.1093/jnci/djt369. Review.

19.

Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies.

Zimmerman JW, Jimenez H, Pennison MJ, Brezovich I, Morgan D, Mudry A, Costa FP, Barbault A, Pasche B.

Chin J Cancer. 2013 Nov;32(11):573-81. doi: 10.5732/cjc.013.10177. Review.

20.

SMAD4 is a potential prognostic marker in human breast carcinomas.

Liu NN, Xi Y, Callaghan MU, Fribley A, Moore-Smith L, Zimmerman JW, Pasche B, Zeng Q, Li YL.

Tumour Biol. 2014 Jan;35(1):641-50. doi: 10.1007/s13277-013-1088-1. Epub 2013 Aug 24.

21.

A comparative phenotypic and genomic analysis of C57BL/6J and C57BL/6N mouse strains.

Simon MM, Greenaway S, White JK, Fuchs H, Gailus-Durner V, Wells S, Sorg T, Wong K, Bedu E, Cartwright EJ, Dacquin R, Djebali S, Estabel J, Graw J, Ingham NJ, Jackson IJ, Lengeling A, Mandillo S, Marvel J, Meziane H, Preitner F, Puk O, Roux M, Adams DJ, Atkins S, Ayadi A, Becker L, Blake A, Brooker D, Cater H, Champy MF, Combe R, Danecek P, di Fenza A, Gates H, Gerdin AK, Golini E, Hancock JM, Hans W, Hölter SM, Hough T, Jurdic P, Keane TM, Morgan H, Müller W, Neff F, Nicholson G, Pasche B, Roberson LA, Rozman J, Sanderson M, Santos L, Selloum M, Shannon C, Southwell A, Tocchini-Valentini GP, Vancollie VE, Westerberg H, Wurst W, Zi M, Yalcin B, Ramirez-Solis R, Steel KP, Mallon AM, de Angelis MH, Herault Y, Brown SD.

Genome Biol. 2013 Jul 31;14(7):R82. doi: 10.1186/gb-2013-14-7-r82.

22.

Differential effects of aspirin before and after diagnosis of colorectal cancer.

Pasche B.

JAMA. 2013 Jun 26;309(24):2598-9. doi: 10.1001/jama.2013.6600. No abstract available. Erratum in: JAMA. 2013 Jul 10;310(2):208.

PMID:
23800937
23.

Influence of internalin A murinisation on host resistance to orally acquired listeriosis in mice.

Bergmann S, Beard PM, Pasche B, Lienenklaus S, Weiss S, Gahan CG, Schughart K, Lengeling A.

BMC Microbiol. 2013 Apr 23;13:90. doi: 10.1186/1471-2180-13-90.

24.

Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.

Costa FP, Gumz B, Pasche B.

Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):843-54. doi: 10.1016/j.bpg.2012.12.001. Review.

PMID:
23582923
25.

Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML.

Borate U, Absher D, Erba HP, Pasche B.

Expert Rev Anticancer Ther. 2012 Oct;12(10):1289-97. doi: 10.1586/era.12.116.

26.

TLR7 contributes to the rapid progression but not to the overall fatal outcome of secondary pneumococcal disease following influenza A virus infection.

Stegemann-Koniszewski S, Gereke M, Orrskog S, Lienenklaus S, Pasche B, Bader SR, Gruber AD, Akira S, Weiss S, Henriques-Normark B, Bruder D, Gunzer M.

J Innate Immun. 2013;5(1):84-96. doi: 10.1159/000345112. Epub 2012 Nov 15.

27.

Aspirin--from prevention to targeted therapy.

Pasche B.

N Engl J Med. 2012 Oct 25;367(17):1650-1. doi: 10.1056/NEJMe1210322. No abstract available.

PMID:
23094728
28.

A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk.

Chen J, Liu RY, Yang L, Zhao J, Zhao X, Lu D, Yi N, Han B, Chen XF, Zhang K, He J, Lei Z, Zhou Y, Pasche B, Li X, Zhang HT.

J Cancer Res Clin Oncol. 2013 Feb;139(2):231-42. doi: 10.1007/s00432-012-1314-z. Epub 2012 Oct 2.

29.

Association between IL6 -174G/C and cancer: A meta-analysis of 105,482 individuals.

Liu RY, Song X, Chen P, Lei Z, Miao J, Yi N, Zhang K, Pasche B, Zhang HT.

Exp Ther Med. 2012 Apr;3(4):655-664. Epub 2012 Jan 13.

30.

Characterization of the colorectal cancer-associated enhancer MYC-335 at 8q24: the role of rs67491583.

Tuupanen S, Yan J, Turunen M, Gylfe AE, Kaasinen E, Li L, Eng C, Culver DA, Kalady MF, Pennison MJ, Pasche B, Manne U, de la Chapelle A, Hampel H, Henderson BE, Marchand LL, Hautaniemi S, Askhtorab H, Smoot D, Sandler RS, Keku T, Kupfer SS, Ellis NA, Haiman CA, Taipale J, Aaltonen LA.

Cancer Genet. 2012 Jan-Feb;205(1-2):25-33. doi: 10.1016/j.cancergen.2012.01.005.

31.

Cancer cell proliferation is inhibited by specific modulation frequencies.

Zimmerman JW, Pennison MJ, Brezovich I, Yi N, Yang CT, Ramaker R, Absher D, Myers RM, Kuster N, Costa FP, Barbault A, Pasche B.

Br J Cancer. 2012 Jan 17;106(2):307-13. doi: 10.1038/bjc.2011.523. Epub 2011 Dec 1.

32.

Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields.

Costa FP, de Oliveira AC, Meirelles R, Machado MC, Zanesco T, Surjan R, Chammas MC, de Souza Rocha M, Morgan D, Cantor A, Zimmerman J, Brezovich I, Kuster N, Barbault A, Pasche B.

Br J Cancer. 2011 Aug 23;105(5):640-8. doi: 10.1038/bjc.2011.292. Epub 2011 Aug 9.

33.

Whole-genome sequencing: a step closer to personalized medicine.

Pasche B, Absher D.

JAMA. 2011 Apr 20;305(15):1596-7. doi: 10.1001/jama.2011.484. No abstract available.

PMID:
21505140
34.

The role of the fat mass and obesity associated gene (FTO) in breast cancer risk.

Kaklamani V, Yi N, Sadim M, Siziopikou K, Zhang K, Xu Y, Tofilon S, Agarwal S, Pasche B, Mantzoros C.

BMC Med Genet. 2011 Apr 13;12:52. doi: 10.1186/1471-2350-12-52.

35.

TGFBR1 signaling and breast cancer.

Moore-Smith L, Pasche B.

J Mammary Gland Biol Neoplasia. 2011 Jun;16(2):89-95. doi: 10.1007/s10911-011-9216-2. Epub 2011 Apr 5. Review.

36.

Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk.

Kaklamani V, Yi N, Zhang K, Sadim M, Offit K, Oddoux C, Ostrer H, Mantzoros C, Pasche B.

Metabolism. 2011 Sep;60(9):1234-43. doi: 10.1016/j.metabol.2011.01.005. Epub 2011 Mar 12.

37.

Bayesian analysis of genetic interactions in case-control studies, with application to adiponectin genes and colorectal cancer risk.

Yi N, Kaklamani VG, Pasche B.

Ann Hum Genet. 2011 Jan;75(1):90-104. doi: 10.1111/j.1469-1809.2010.00605.x. Epub 2010 Sep 15.

38.

Schistosoma co-infection protects against brain pathology but does not prevent severe disease and death in a murine model of cerebral malaria.

Bucher K, Dietz K, Lackner P, Pasche B, Fendel R, Mordmüller B, Ben-Smith A, Hoffmann WH.

Int J Parasitol. 2011 Jan;41(1):21-31. doi: 10.1016/j.ijpara.2010.06.008. Epub 2010 Aug 12.

PMID:
20708623
39.

Cancer genetics. Introduction.

Pasche B.

Cancer Treat Res. 2010;155:xi-xii. No abstract available.

PMID:
20698080
40.

Tgf-beta signaling alterations and colon cancer.

Bellam N, Pasche B.

Cancer Treat Res. 2010;155:85-103. doi: 10.1007/978-1-4419-6033-7_5. Review.

PMID:
20517689
41.

Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs.

Pasche B, Wisinski KB, Sadim M, Kaklamani V, Pennison MJ, Zeng Q, Bellam N, Zimmerman J, Yi N, Zhang K, Baron J, Stram DO, Hayes MG.

J Exp Clin Cancer Res. 2010 May 25;29:57. doi: 10.1186/1756-9966-29-57.

42.

Genetic/familial high-risk assessment: breast and ovarian.

Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarski R, Reiser G, Shannon KM, Smith JR, Swisher E, Weitzel JN; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2010 May;8(5):562-94. No abstract available.

PMID:
20495085
43.

Candidate gene association studies: successes and failures.

Pasche B, Yi N.

Curr Opin Genet Dev. 2010 Jun;20(3):257-61. doi: 10.1016/j.gde.2010.03.006. Epub 2010 Apr 21. Review.

44.

Caring for patients with cancer.

Pasche B, McNutt RA, Fontanarosa PB.

JAMA. 2010 Mar 17;303(11):1094-5. doi: 10.1001/jama.2010.285. No abstract available.

PMID:
20233832
45.

The cover. Physichromie no. 965.

Pasche B.

JAMA. 2010 Mar 17;303(11):1015. doi: 10.1001/jama.2010.220. No abstract available.

PMID:
20233811
46.

Tgfbr1 haploinsufficiency inhibits the development of murine mutant Kras-induced pancreatic precancer.

Adrian K, Strouch MJ, Zeng Q, Barron MR, Cheon EC, Honasoge A, Xu Y, Phukan S, Sadim M, Bentrem DJ, Pasche B, Grippo PJ.

Cancer Res. 2009 Dec 15;69(24):9169-74. doi: 10.1158/0008-5472.CAN-09-1705.

47.

TGFBR1 haplotypes and risk of non-small-cell lung cancer.

Lei Z, Liu RY, Zhao J, Liu Z, Jiang X, You W, Chen XF, Liu X, Zhang K, Pasche B, Zhang HT.

Cancer Res. 2009 Sep 1;69(17):7046-52. doi: 10.1158/0008-5472.CAN-08-4602. Epub 2009 Aug 18.

48.

One step forward toward identification of the genetic signature of glioblastomas.

Pasche B, Myers RM.

JAMA. 2009 Jul 15;302(3):325-6. doi: 10.1001/jama.2009.1023. No abstract available.

PMID:
19602695
49.

Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach.

Barbault A, Costa FP, Bottger B, Munden RF, Bomholt F, Kuster N, Pasche B.

J Exp Clin Cancer Res. 2009 Apr 14;28:51. doi: 10.1186/1756-9966-28-51.

50.

Transforming growth factor beta as a therapeutic target in systemic sclerosis.

Varga J, Pasche B.

Nat Rev Rheumatol. 2009 Apr;5(4):200-6. doi: 10.1038/nrrheum.2009.26. Review.

Supplemental Content

Loading ...
Support Center